Groundbreaking AI Study Transforms Cancer Diagnostics
Lunit, in partnership with Japan’s National Cancer Center Hospital East (NCCHE), has published breakthrough research in the Journal of Clinical Oncology Precision Oncology. Their study demonstrates how AI-powered pathology…
Researchers from The Chinese University of Hong Kong and Beijing Tongren Hospital have developed a foundational AI model for automated eye disease diagnosis. WHAT IT’S ABOUT
The generative AI model, VisionFM, was pre-trained on a large ophthalmic data…
Strategic Acquisition Enhances AI Capabilities
ScreenPoint Medical’s acquisition of Biomediq A/S on January 8, 2025, represents a milestone in AI-driven breast cancer detection. This strategic merger follows ten years of collaborative research, integrating Biomediq’s quantitative…
Aging affects the 12-lead electrocardiogram (ECG) and correlates with cardiovascular disease (CVD). AI-ECG models estimate aging effects as a novel biomarker but have only been evaluated on single ECGs—without utilizing longitudinal data. We validated…
Continue Reading
Remote, digital cognitive testing on an individual’s own device provides the opportunity to deploy previously understudied but promising cognitive paradigms in preclinical Alzheimer’s disease (AD). The Boston Remote Assessment for NeuroCognitive Health (BRANCH) captures…
Continue Reading
What You Should Know:
– ScreenPoint Medical, a provider of AI-powered breast cancer screening solutions, acquires Biomediq A/S, a research-based company specializing in quantitative imaging biomarkers. Financial details of the acquisition were not disclosed.
– ScreenPoint’s…
Continue Reading
Henry O’Connell, CEO and Co-Founder, Canary Speech
In recent years, the use of AI-enhanced ambient listening tools has transformed the way clinicians utilize vocal biomarkers for cognitive and behavioral health assessments. As these technologies expand, clinicians are exploring…
Continue Reading
What You Should Know:
– Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced its upcoming acquisition by Renovaro, Inc. (NASDAQ: RENB) in a strategic move aimed at accelerating innovation and improving…
Continue Reading
Estimating progression of acute ischemic brain lesions – or biological lesion age – holds huge practical importance for hyperacute stroke management. The current best method for determining lesion age from non-contrast computerised tomography (NCCT),…
Continue Reading
What You Should Know:
– ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization.
– CTO-H provides a research data solution that is…
Continue Reading
